Wockhardt Ltd continued its downward trajectory, dropping 0.67% to ₹1,936.7 as of 13:19 IST on the NSE, marking its fifth straight session of losses. According to reports from Business Standard, the pharmaceutical stock's decline occurred despite the broader market showing mixed performance, with the benchmark NIFTY down 0.08% at 23,927.75 and the Sensex at 76,618.81, down 0.14%.
Despite the recent decline, Wockhardt Ltd has demonstrated strong annual performance, jumping 87.69% over the past year, significantly outperforming the NIFTY's 6.32% slide and the Nifty Pharma index's 15.05% surge. As reported by Business Standard, the stock has also experienced a 10.04% decline over the last month, contrasting with the Nifty Pharma index's 4.72% increase during the same period. The Nifty Pharma index is currently quoting at 25,227.9, up 0.51% on the day, highlighting the divergence between the pharmaceutical sector's performance and Wockhardt's recent struggles.
Trading activity in Wockhardt Ltd showed reduced participation with 3.28 lakh shares traded today, substantially lower than the 28.63 lakh shares average volume recorded in the last month. According to Business Standard, the stock's PE ratio stands at 108.46 based on trailing twelve months earnings ending March 2026, reflecting its premium valuation within the pharmaceutical sector. The current trading volume of 3.28 lakh shares represents a significant decrease from the 28.63 lakh shares average, indicating reduced investor interest during this extended decline period.
